Janice P. Dutcher, MD | Authors

ASIAN HOSPITAL & MEDICAL CTR

RM 719 MOB CIVIC DRIVE FILINVE

Articles

Integrating Innovative Therapeutic Strategies Into the Management of Renal Cell Carcinoma

June 15, 2012

In the current critical review we discuss these emerging trends in localized and systemic treatment as well as possible interesting combinations of the two modalities. Finally, we discuss the role of the new systemic agents in non–clear cell RCC.

High-Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma and Metastatic Melanoma: Still the Standard

April 30, 2011

My 2002 article provided an overview of the various interleukin-2 (IL-2)–based treatment regimens that had been explored over the preceding two decades

High-Dose Interleukin-2 in Metastatic Disease: Renal Cell Carcinoma and Melanoma

November 01, 2002

Despite significant advances in the treatment of a variety of malignancies, highly effective therapies for most patients with metastatic renal cell carcinoma or metastatic melanoma are rare. Traditional oncologic treatment methods, such as

Current Status of Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma and Metastatic Melanoma

November 01, 2002

Interleukin-2 (IL-2, Proleukin) is one of the most effective agents in the treatment of metastatic renal cell carcinoma and metastatic melanoma. High-dose IL-2 therapy produces overall response rates of 15% to 20%;

Managing Toxicities of High-Dose Interleukin-2

November 01, 2002

Although high-dose interleukin-2 (IL-2, Proleukin), a highly toxic agent used in the treatment of renal cell carcinoma and melanoma, was initially associated with treatment-related mortality, it can, in the appropriate

Commentary (Dutcher/Wiernik): Current Management of Acute Lymphoblastic Leukemia in Adults

May 01, 1995

Acute lymphoblastic leukemia (ALL) in adults is clearly a "different disease" than ALL in children-a fact that is well documented in the article by Ong and Larson. As they indicate, more than half of adult patients relapse despite modern therapy, most within the first 2 years. It should be pointed out, however, as is mentioned at the beginning of the article, that "modern" induction was defined by Cancer and Leukemia Group B study 7612--a study begun in 1976 [1]. Thus, induction therapy has not changed substantially in 20 years. The addition of consolidation therapy and prolonged maintenance therapy has resulted in modest increases in response duration, but despite many variations on current regimens, there has been little change in outcome during the past decade.